 BOSTON--BUSINESS WIRE--AVEO Oncology Nasdaq: AVEO, a commercial and clinical development stage biopharmaceutical company, today announced the presentation of additional data from the Phase 3 TIVO-3 study comparing FOTIVDA tivozanib to sorafenib in relapsed or refractory advanced renal cell carcinoma RCC following two or more prior systemic therapies. The data, which includes updated durability of response DOR and overall survival OS results, as well as an analysis of treatment-emer 